Jasper Therapeutics, Inc. - JSPR STOCK NEWS

Jasper Therapeutics (Nasdaq: JSPR) announced the appointment of David Hinds as Senior Vice President of Development Operations on April 10, 2023. Hinds, who has over 25 years of experience in clinical program development, is expected to play a crucial role in advancing briquilimab, an antibody therapy targeting c-Kit (CD117). This therapy aims to treat chronic spontaneous urticaria and lower-risk myelodysplastic syndromes (MDS) while enhancing stem cell transplant conditioning. CEO Ronald Martell expressed confidence in Hinds' ability to lead the clinical development phase effectively, including studies for chronic spontaneous urticaria and MDS. Jasper has demonstrated briquilimab's safety and efficacy in over 130 subjects and aims to further its development in various therapeutic areas.

Jasper Therapeutics, Inc. (NASDAQ: JSPR) announced its participation in the Cantor Fitzgerald The Future of Oncology Virtual Symposium from April 3-5, 2023. Senior Vice President Wendy Pang will join a panel discussion on April 5 at 1:00 PM ET, addressing novel mechanisms for hematological malignancies. Jasper is developing briquilimab, a monoclonal antibody targeting c-Kit (CD117) for conditions like chronic spontaneous urticaria and lower to intermediate risk myelodysplastic syndromes (MDS). The therapy has shown promising safety and efficacy in over 130 subjects, with implications for stem cell transplants in rare diseases.

Jasper Therapeutics (Nasdaq: JSPR) has appointed Daniel Adelman, M.D., as its Acting Chief Medical Officer. Adelman brings over 30 years of experience in clinical development, particularly for immunologic diseases, holding leadership roles at companies such as Aimmune and Genentech. CEO Ron Martell expressed enthusiasm about Adelman's addition, citing his expertise as crucial for advancing their novel antibody therapy, briquilimab. This drug targets c-Kit for conditions like chronic spontaneous urticaria and myelodysplastic syndromes. Briquilimab has shown promising efficacy and safety in over 130 subjects, positioning Jasper for potential market success.

Jasper Therapeutics (NASDAQ: JSPR), a biotechnology firm, is focusing on innovative antibody therapies for chronic spontaneous urticaria and myelodysplastic syndromes (MDS). The company announced participation in key conferences in March 2023, including:

• William Blair’s Innovator Series on March 13, featuring CEO Ronald Martell discussing New Therapies in Urticaria.
• Oppenheimer 33rd Annual Healthcare Conference on the same day, where Martell will present the company's corporate updates.

Details for the live webcasts can be found on Jasper's Investor Events page.

Jasper Therapeutics (Nasdaq: JSPR) announced a strategic expansion of its briquilimab development to include chronic spontaneous urticaria. The company raised $101.4 million in net proceeds in January 2023, enhancing its funding for ongoing clinical trials. Fiscal 2022 net loss was $37.7 million, up from $30.6 million in 2021, with R&D expenses rising to $34.6 million from $25.4 million. Jasper presented initial positive clinical data from a Phase I/II trial for sickle cell disease and successful one-year follow-up data for acute myeloid leukemia patients, with 12 out of 12 AML patients achieving donor cell engraftment.

Jasper Therapeutics (Nasdaq: JSPR) has appointed Vishal Kapoor to its Board of Directors. Kapoor, a healthcare veteran, is currently a Partner at Avego Management and previously led the life sciences venture strategy at Amplitude Healthcare Acquisition Corp. He has significant experience in developing therapeutic assets in biotechnology, having worked with Iveric bio and Genentech. The company, well-funded from a recent public offering, aims to advance its lead candidate, briquilimab, targeting c-Kit for chronic diseases and as a conditioning agent for stem cell transplants. The appointment is expected to enhance Jasper's strategic direction.

Jasper Therapeutics (Nasdaq: JSPR) announced promising results from a Phase 1/2 study of briquilimab as a conditioning agent for patients with Fanconi Anemia. Both patients exhibited successful neutrophil engraftment within 11 days, achieving 100% donor chimerism after six and three months, respectively. Briquilimab showed no treatment-related adverse events and was cleared by day 9 post-dosing. The study aims to reduce toxicity associated with traditional conditioning therapies like busulfan chemotherapy.

This update enhances confidence in briquilimab's potential to treat various patient groups effectively.

Jasper Therapeutics (Nasdaq: JSPR) announced promising Phase 1 results for briquilimab in treating acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) at the 2023 Tandem Meetings. Key findings show that all 12 AML patients achieved successful neutrophil engraftment, with a median recovery time of 19 days. Notably, 67% of patients remain free from relapse, and the conditioning regimen demonstrated a favorable safety profile with no significant adverse events. Additionally, the outpatient treatment model potentially reduces the clinical and economic burden of stem cell transplants.

Jasper Therapeutics presented promising data for its briquilimab treatment for sickle cell disease at the 2023 Transplantation & Cellular Therapy Meetings. The first two participants achieved 100% donor myeloid chimerism by Day 100, while a third participant reached this milestone by Day 30. Notably, all participants showed increased hemoglobin levels at their most recent follow-up, with values reaching 12.6 g/dL, 11.4 g/dL, and 14 g/dL. These findings, presented by Dr. John F. Tisdale, highlight the potential of briquilimab as a conditioning agent in stem cell transplants, indicating a significant step forward in addressing unmet needs in sickle cell disease treatment.